Chordia Therapeutics Awarded 30 Million Yen AMED Grant for Cancer Therapy Research

MT Newswires Live

06/19

Chordia Therapeutics (TYO:190A) has been selected to receive a 30 million yen grant for the fiscal year ending March 2026, stemming from a subcontract research and development agreement with Kyoto University, according to Tokyo bourse filing on Thursday.

This funding is for a non-clinical study on novel therapeutic agents for refractory tumours with RNA splicing mutations, under the Japan Agency for Medical Research and Development's (AMED) Research Project for Innovative Cancer Therapy Application.

While this grant will be recorded as non-operating income, it is not expected to impact Chordia's business forecast for the current fiscal year.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2544135754"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544135754\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544135754?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-19 11:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544135754","market":"us","top_or_hot":-1,"title":"Chordia Therapeutics Awarded 30 Million Yen AMED Grant for Cancer Therapy Research","media":"MT Newswires Live","content":"<html><body><p> Chordia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TYO:190A) has been selected to receive a 30 million yen grant for the fiscal year ending March 2026, stemming from a subcontract research and development agreement with Kyoto University, according to Tokyo bourse filing on Thursday.</p><p>This funding is for a non-clinical study on novel therapeutic agents for refractory tumours with RNA splicing mutations, under the Japan Agency for Medical Research and Development's (AMED) Research Project for Innovative Cancer Therapy Application.</p><p>While this grant will be recorded as non-operating income, it is not expected to impact Chordia's business forecast for the current fiscal year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chordia Therapeutics Awarded 30 Million Yen AMED Grant for Cancer Therapy Research</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChordia Therapeutics Awarded 30 Million Yen AMED Grant for Cancer Therapy Research\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-06-19 11:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Chordia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TYO:190A) has been selected to receive a 30 million yen grant for the fiscal year ending March 2026, stemming from a subcontract research and development agreement with Kyoto University, according to Tokyo bourse filing on Thursday.</p><p>This funding is for a non-clinical study on novel therapeutic agents for refractory tumours with RNA splicing mutations, under the Japan Agency for Medical Research and Development's (AMED) Research Project for Innovative Cancer Therapy Application.</p><p>While this grant will be recorded as non-operating income, it is not expected to impact Chordia's business forecast for the current fiscal year.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2544135754","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544135754","pubTimestamp":1750303739,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Chordia Therapeutics  has been selected to receive a 30 million yen grant for the fiscal year ending March 2026, stemming from a subcontract research and development agreement with Kyoto University, according to Tokyo bourse filing on Thursday.This funding is for a non-clinical study on novel therapeutic agents for refractory tumours with RNA splicing mutations, under the Japan Agency for Medical Research and Development's  Research Project for Innovative Cancer Therapy Application.While this grant will be recorded as non-operating income, it is not expected to impact Chordia's business forecast for the current fiscal year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4539":"次新股","AMED":"阿米斯医疗","LENZ":"Therapeutics","BK4139":"生物科技","BK4196":"保健护理服务"},"translate_title":"Chordia Therapeutics获得3000万日元AMED资助用于癌症治疗研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMED":1,"LENZ":1},"content_text":"Chordia Therapeutics (TYO:190A) has been selected to receive a 30 million yen grant for the fiscal year ending March 2026, stemming from a subcontract research and development agreement with Kyoto University, according to Tokyo bourse filing on Thursday.This funding is for a non-clinical study on novel therapeutic agents for refractory tumours with RNA splicing mutations, under the Japan Agency for Medical Research and Development's (AMED) Research Project for Innovative Cancer Therapy Application.While this grant will be recorded as non-operating income, it is not expected to impact Chordia's business forecast for the current fiscal year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}